Aloop Therapeutics ApS: Financial statements 2024
CVR: 43257498
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Aloop Therapeutics ApS (CVR 43257498) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -1,323,042 and a net result of DKK -1,295,153 compared with DKK -8,808,915 the year before. Equity in the 2024 report amounted to DKK 30,727,192. The solvency ratio was 99.7%.
- Gross Profit
- DKK -1,323,042
- Profit/Loss
- DKK -1,295,153
- Equity
- DKK 30,727,192
- Total Assets
- DKK 30,814,026
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -1.3M | -1.3M | 30.7M | - |
| 2023 | - | -9.1M | -8.8M | 32M | 8 |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
As of March 31, 2024, Thomas Kirkegaard Jensen has stepped down as director of Aloop Therapeutics ApS.
Aloop Therapeutics ApS has published its annual report for 2023. Gross profit came to DKK -9,058,291, and the net result was DKK -8,808,915.
As of February 29, 2024, PKF Munkebo Eriksen Funch, Statsautoriseret Revisionsaktieselskab has stepped down as auditor of Aloop Therapeutics ApS.
About Aloop Therapeutics ApS
Aloop Therapeutics ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2022. The company is registered under the industry Fremstilling af farmaceutiske præparater. The management consists of Rodolphe Clerval. The company is owned by Coave Therapeutics. The company has 6 employees (2024). In 2025, the company reported a gross profit of DKK -274,227 and a net result of DKK -69,892 compared with DKK -1,295,153 the year before. Equity in the 2025 report amounted to DKK 30,657,300.
